Shots:
Sling Therapeutics has dosed the first patients in the global P-III (ORBIT) trial assessing linsitinib (150mg, PO, BID) vs PBO in ~130 adults with mod. to sev. active thyroid eye disease (TED) for 24wks.
The trial will assess the proportion of proptosis responders at Wk. 24, defined as a ≥2 mm reduction in the…
